Synthesis of hydroxyapatite from mussel shells for effective adsorption of aqueous Cd(II).

We report the synthesis of hydroxyapatite (HAP) powder from waste mussel shells (decomposed to CaO) and phosphoric acid at room temperature without pH control. The powder synthesized was utilized for cadmium removal from aqueous solutions using the batch technique. The effects of solution pH, adsorbent dose; initial Cd2+ concentration, contact time, and temperatures were examined. Furthermore, the adsorption process revealed a pseudo-second-order reaction model and the Langmuir isotherm is the best-fit model to predict the experimental data and adsorption capacity was found to be 62.5 mg/g. Thermodynamic analysis revealed that because of the negative values of ΔGo and the positive value of ΔHo, the adsorption process was spontaneous and endothermic. Cadmium immobilization occurs through a two step mechanism: rapid ion exchange followed by partial dissolution of hydroxapatite and precipitation of cadmium containing hydroxyapatite.

Elaboration of the hydroxyapatite with different precursors and application for the retention of the lead.

Carbonate hydroxyapatite (CHAP) was synthesized from different precursors; synthetic (CaCO3 and Ca(OH)2) and natural (egg shell before and after calcinations at 900 degrees C) under different conditions and characterized by using TG/DTG analysis, X-ray powder diffraction (XRD) method and Fourier transform infrared (FT-IR) spectroscopy techniques. The results of these analyses indicate that the four powders present the same structure of hydroxyapatite. Furthermore the four powders obtained were used for the retention of lead. The results obtained indicated that all powders present high adsorption capacity for lead, but from environmental and economic views, the hydroxyapatite synthesized from eggshell no calcined (HA2) is most advantageous. The influence of different sorption parameters, such as: initial metal concentration, equilibration time, solution pH and sorbent dosage was studied and discussed.

Factorial design analysis for sorption of zinc on hydroxyapatite.

A factorial design was employed to evaluate the quantitative removal of zinc from aqueous solutions on synthesized hydroxyapatite. The experimental factors and their respective levels studied were the initial zinc concentration in solution (35≤C(Zn)≤85 mg/L), adsorbent dosage (4.5≤C(susp)≤9.5 g/L), Ca/P molar ratio (1.667≤Ca/P≤2) and calcination temperature of hydroxyapatite (600≤T(Cal)≤800 °C). The adsorption parameters were analysed statistically by means of variance analysis by using the STATISTICA software. The experimental results and statistical analysis show that increasing in the calcination temperature from 600 to 800 °C decrease the zinc adsorption whereas the increase of adsorbent dosage increases it. Based on the analysis of variance and the factorial design of experiments, adsorbent dosage has a positive effect on the removal of zinc, whereas zinc concentration, Ca/P molar ratio and calcination temperature have a negative effect on this process. The factorial results also demonstrate the existence of statistically significant binary interactions of the experimental factors. The experimental results were fitted to the Langmuir and Freundlich equations to find out adsorption capacities. In most cases, the results indicate that the sorption data fits well in the Freundlich isotherm model. The results of XRD analysis, pH(PZC) and pH(Final) values indicated that ion exchange and dissolution/precipitation mechanisms predominate for the sorption of zinc on our hydroxyapatite.

[The Mydriasert insert: an alternative to eye drops for preangiographic mydriasis]. / L'insert ophtalmique Mydriasert, une alternative aux collyres pour la mydriase pré-angiographie.

PURPOSE: Mydriasert is an insoluble ophthalmic insert, gradually releasing two well-known active ingredients: phenylephrine and tropicamide. It is indicated in presurgical mydriasis. The purpose was to evaluate its efficacy in obtaining mydriasis required for fluorescein angiography. MATERIAL AND METHODS: The ability of Mydriasert to provide mydriasis (defined by a pupillary diameter of at least 7 mm) compatible with a bilateral angiographic examination in optimal conditions was evaluated by a comparative, randomised versus active treatment (eye drops) open trial in 72 patients. RESULTS: All the patients obtained a stable mydriasis allowing angiography. In the Mydriasert group, mydriasis preparation required a mean of 10 min more (Student t test: p<0.001); however, near eyesight recovery was 15 min shorter on average (log-rank test<0.01%) and amounts of active ingredients administered to provide mydriasis were 5-10 times higher in the eye drops reference group. Cardiovascular parameters remained in the normal range in both groups. Three patients of the Mydriasert group presented one ocular symptom of local intolerance, which disappeared in 15 min (exact Fisher test not significant between the treatment groups, p=0.2394). No superficial punctate keratitis was detected during the trial. CONCLUSION: The treatment by Mydriasert can prepare preangiographic mydriasis as well as the reference treatment. The time required for mydriasis is slightly longer. Near eyesight recovery, faster with Mydriasert, could provide an improvement in patient safety and comfort at the end of the ophthalmologic visit.

High-performance liquid chromatographic determination of phenylephrine and tropicamide in human aqueous humor.

A high-performance liquid chromatographic method for the simultaneous determination of phenylephrine and tropicamide in human aqueous humor was developed. After centrifugation, an aliquot of the supernatant was injected onto the column and the eluent was monitored at 280 nm then 254 nm after 5 min. Separation was performed on a CN column with 0.01 M Pic B8 (octane sulfonic acid)-acetonitrile (65:35, v/v) as mobile phase. The standard curves were linear in the detection range. The precision of the method (expressed by relative standard deviation) and the accuracy (mean error in per cent) were <5% for both intra- and interassays.

The formulation of drug for ocular administration.

The different barriers that slow the penetration of active ingredients administered by the ocular route are described, and some novel dosage forms designed for this route are discussed. Both precorneal and corneal factors considerably restrict ocular penetration. The low bioavailability of classical ophthalmic dosage forms can be improved by several approaches, particularly by increasing the time the active ingredients remain in contact with the eye tissues. The new dosage forms are reviewed according to their type and their drug release mechanisms. The characteristics, advantages, and limitations of each are outlined. The potential of these dosage forms can be expected to enhance development. They offer prolonged effectiveness, reproducibility, fewer unwanted side effects, and improved tolerance.